NCT04543279View on ClinicalTrials.gov

Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

May 3, 2021

Primary Completion Date

July 1, 2022

Study Completion Date

July 30, 2022

Conditions
MyelofibrosisThrombocytopenia
Interventions
DRUG

Fostamatinib

Fostamatinib will be supplied by Rigel Pharmaceuticals.

DRUG

Ruxolitinib

Ruxolitinib is commercially available.

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Rigel Pharmaceuticals
All Listed Sponsors
collaborator

Rigel Pharmaceuticals

INDUSTRY

lead

Washington University School of Medicine

OTHER